{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:50:07Z","timestamp":1782471007311,"version":"3.54.5"},"reference-count":34,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Background\/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) highlights the central role of metabolic dysregulation in hepatic steatosis. Patients with inflammatory bowel disease (IBD) are increasingly recognized to have an adverse cardiometabolic risk profile; however, data regarding MASLD prevalence and associated factors in this population remain limited, particularly in regions with a high metabolic burden such as T\u00fcrkiye. This study aimed to determine the prevalence of MASLD in patients with IBD and to identify the metabolic and disease-related factors associated with its development. Methods: In this retrospective cross-sectional study, adult patients with IBD followed at a tertiary referral center in T\u00fcrkiye were included. Hepatic steatosis was assessed using routine abdominal imaging, and MASLD was defined according to the 2023 Delphi Consensus criteria. Clinical, demographic, and metabolic variables were analyzed. Multivariable logistic regression analysis was performed to identify factors independently associated with MASLD. Results: A total of 194 IBD patients who had abdominal imaging available within the previous 6 months were included, of whom 61.3% had MASLD. MASLD was more prevalent in patients with UC than in those with CD (70.7% vs. 55.5%, p = 0.036). However, UC diagnosis was not independently associated with MASLD after multivariable adjustment. Patients with MASLD were older and had higher body mass index and less favorable metabolic profiles. In multivariable analysis, age (OR 1.055, 95% CI 1.022\u20131.089; p &lt; 0.001), body mass index (OR 1.199, 95% CI 1.092\u20131.316; p &lt; 0.001), and triglyceride levels (OR 1.012, 95% CI 1.004\u20131.020; p = 0.005) were independently associated with MASLD. In contrast, disease-related factors, including disease activity, biologic therapy, and prior surgery, were not independently associated with MASLD. Conclusions: MASLD prevalence was high among selected IBD patients with available abdominal imaging and appears to be more strongly associated with metabolic risk factors than with disease-specific characteristics. In populations with a high background cardiometabolic burden, MASLD in IBD may largely reflect the underlying regional metabolic milieu. These findings support the integration of metabolic risk assessment and proactive MASLD screening into routine IBD care. Prospective longitudinal studies are needed to clarify the causal relationship between metabolic dysfunction, IBD-related factors, and MASLD progression.<\/jats:p>","DOI":"10.3390\/metabo16070450","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T08:43:57Z","timestamp":1782463437000},"page":"450","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic Dysfunction-Associated Steatotic Liver Disease in Inflammatory Bowel Disease: A Cross-Sectional Study of Prevalence and Associated Factors"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7827-8115","authenticated-orcid":false,"given":"H\u00fcseyin","family":"Aykut","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Umraniye Training and Research Hospital, 34764 Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0486-1767","authenticated-orcid":false,"given":"Nermin Mutlu","family":"Bilgi\u00e7","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Umraniye Training and Research Hospital, 34764 Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9004-730X","authenticated-orcid":false,"given":"Duygu","family":"Demirta\u015f","sequence":"additional","affiliation":[{"name":"Department of Radiology, Umraniye Training and Research Hospital, University of Health Sciences, 34764 Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3476-2375","authenticated-orcid":false,"given":"S\u00fcleyman","family":"Sayar","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, VM Medical Park Pendik Hospital, 34899 Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2556-3064","authenticated-orcid":false,"given":"Kamil","family":"\u00d6zdil","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Memorial Atasehir Hospital, 34634 Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"105472","DOI":"10.3748\/wjg.v31.i18.105472","article-title":"Current and forecasted 10-year prevalence and incidence of inflammatory bowel disease in Hong Kong, Japan, and the United States","volume":"31","author":"Zhang","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjae082","article-title":"Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies","volume":"18","author":"Caron","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_3","first-page":"618","article-title":"Epidemiology of metabolic syndrome in patients with inflammatory bowel disease: A population-level cohort study from the United States","volume":"38","author":"Desai","year":"2025","journal-title":"Ann. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/liv.15852","article-title":"Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa","volume":"44","author":"Younossi","year":"2024","journal-title":"Liver Int."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kirik, A., Sumbul, H.E., Koca, N., Pa\u015fal\u0131 Kilit, T., Demiral Sezer, S., Binnetoglu, E., Ara\u00e7, E., Solmaz, \u0130., \u015een, H., and Demirci, \u0130. (2025). Prevalence of MASLD and Fibrosis Risk in Turkish Adults with Cardiometabolic Risk Factors: A Nationwide Multicenter Study (DAHUDER MASLD Study). J. Clin. Med., 14.","DOI":"10.3390\/jcm14197098"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e34915","DOI":"10.1016\/j.heliyon.2024.e34915","article-title":"Prevalence of metabolic dysfunction-associated steatotic liver disease and steatohepatitis in T\u00fcrkiye: A forensic autopsy study","volume":"10","author":"Ergenc","year":"2024","journal-title":"Heliyon"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.5152\/tjg.2021.20062","article-title":"The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade","volume":"32","author":"Demir","year":"2021","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Wang, J., and Sun, H. (2025). Prevalence of non-alcoholic fatty liver disease among inflammatory bowel disease patients: A systematic review and meta-analysis. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1517462"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Navarro, P., Guti\u00e9rrez-Ram\u00edrez, L., Tejera-Mu\u00f1oz, A., Arias, \u00c1., and Lucendo, A.J. (2023). Systematic Review and Meta-Analysis: Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Inflammatory Bowel Disease. Nutrients, 15.","DOI":"10.3390\/nu15214507"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/ibd\/izaa189","article-title":"Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis","volume":"27","author":"Lin","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/apt.16879","article-title":"Meta-analysis: Prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"55","author":"Zamani","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e20231321","DOI":"10.1590\/1806-9282.20231321","article-title":"Metabolic dysfunction-associated steatotic liver disease prevalence and risk factors in inflammatory bowel disease in tertiary center","volume":"70","author":"Oliveira","year":"2024","journal-title":"Rev. Assoc. Med. Bras."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"i871","DOI":"10.1093\/ecco-jcc\/jjae190.0557","article-title":"P0383 Factors associated with steatotic liver disease associated with metabolic dysfunction (MASLD) in patients with Inflammatory Bowel Disease (IBD)","volume":"19","author":"Oliveira","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"i2286","DOI":"10.1093\/ecco-jcc\/jjae190.1438","article-title":"P1264 Metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with Inflammatory Bowel Disease (IBD). A prospective single-center study","volume":"19","author":"Pastras","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"i2176","DOI":"10.1093\/ecco-jcc\/jjae190.1376","article-title":"P1202 Metabolic-dysfunction associated liver disease in patient with Inflammatory Bowel Disease: Is obesity the major driver of disease progression?","volume":"19","author":"Melatti","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Abenavoli, L., Spagnuolo, R., Scarlata, G.G.M., Gambardella, M.L., Boccuto, L., M\u00e9ndez-S\u00e1nchez, N., and Luzza, F. (2024). Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Inflammatory Bowel Diseases: A Pilot Study. Life, 14.","DOI":"10.3390\/life14101226"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5472\/marumj.570907","article-title":"Prevalence of fatty liver disease in patients with inflammatory bowel disease: A transient elastography study on the basis of a controlled attenuation parameter","volume":"32","year":"2019","journal-title":"Marmara Med. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S363","DOI":"10.1093\/ecco-jcc\/jju027.683","article-title":"P565 The Increased Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients is not Related to Inflammatory Load","volume":"9","author":"Erzin","year":"2015","journal-title":"J. Crohns Colitis"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S619","DOI":"10.1093\/ecco-jcc\/jjz203.911","article-title":"P783 Non-alcoholic fatty liver disease and advanced liver disease in patients with inflammatory bowel disease: Prevalence and risk factors","volume":"14","author":"Demir","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s43162-025-00470-5","article-title":"Prevalence of metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease patients: An Egyptian cross-sectional study","volume":"37","author":"Hamed","year":"2025","journal-title":"Egypt. J. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.3748\/wjg.v26.i46.7367","article-title":"Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: A cross-sectional and longitudinal analysis","volume":"26","author":"Hoffmann","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/ibd\/izy200","article-title":"Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography","volume":"25","author":"Restellini","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/1744666X.2025.2514605","article-title":"Metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease: Prevalence, risk factors, pathophysiological pathways and clinical consequences","volume":"21","author":"Lucendo","year":"2025","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Maresca, R., Mignini, I., Varca, S., Calvez, V., Termite, F., Esposto, G., Laterza, L., Scaldaferri, F., Ainora, M.E., and Gasbarrini, A. (2024). Inflammatory Bowel Diseases and Non-Alcoholic Fatty Liver Disease: Piecing a Complex Puzzle Together. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063278"},{"key":"ref_27","first-page":"463","article-title":"High prevalence of non-alcoholic fatty liver disease in patients with inflammatory bowel disease receiving anti-tumor necrosis factor therapy","volume":"32","author":"Likhitsup","year":"2019","journal-title":"Ann. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/MCG.0000000000001727","article-title":"Steroid Use and Risk of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease: Systematic Review and Meta-analysis","volume":"57","author":"Trivedi","year":"2023","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.22551\/2025.48.1203.10321","article-title":"MASLD risk prediction in IBD: Development of two tailored clinical scores","volume":"12","author":"Stafie","year":"2025","journal-title":"Arch. Clin. Cases"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"101293","DOI":"10.1016\/j.jceh.2023.10.004","article-title":"Prevalence, Predictors, and Impact of Hepatic Steatosis in Patients with Ulcerative Colitis: A Prospective Observational Cohort Study","volume":"14","author":"Gupta","year":"2024","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Fousekis, F., Lamprou, A., Saridi, M., Mastorogianni, I.N., Mpakogiannis, K., Lianos, G.D., and Katsanos, K.H. (2026). Metabolic Disorders and Inflammatory Bowel Diseases: Unraveling Shared Pathways and Clinical Interactions. Metabolites, 16.","DOI":"10.3390\/metabo16030181"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"9420002","DOI":"10.26599\/FMH.2024.9420002","article-title":"Cornus officinalis vinegar alters the gut microbiota, regulating lipid droplet changes in nonalcoholic fatty liver disease model mice","volume":"1","author":"Cao","year":"2024","journal-title":"Food Med. Homol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"9420077","DOI":"10.26599\/FMH.2025.9420077","article-title":"Potential of Dendrobium officinale oligosaccharides to alleviate chronic colitis by modulating inflammation and gut microbiota","volume":"2","author":"Shi","year":"2025","journal-title":"Food Med. Homol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/ibd\/izad175","article-title":"Inflammatory Bowel Disease Is an Independent Risk Factor for Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals","volume":"30","author":"Callau","year":"2024","journal-title":"Inflamm. Bowel Dis."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/7\/450\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:08:07Z","timestamp":1782468487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/7\/450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["metabo16070450"],"URL":"https:\/\/doi.org\/10.3390\/metabo16070450","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]}}}